Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone as Add-On Therapy in Ischemic Stroke
IRCT20241220064106N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pioglitazone in ischemic stroke, sponsored by Hamadan University of Medical Sciences. Primary endpoint: Change in NIH Stroke Scale score. Started Mar 2025; status: completed.
02
Drugs
pioglitazone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20241220064106N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241220064106N1.